teva-english-logo-gray
4 October 2013Europe

Teva wins Netherlands Copaxone case

Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

The Hague court rejected Mylan’s attempt to have Teva’s patent for the drug revoked, dismissing all the grounds of invalidity raised. Teva’s European patent (NL)762,888 expires in 2015.

Copaxone is approved for treatment in more than 50 countries, and has sales of more than $1 billion per quarter.

The same patent was challenged in the UK this year, with the Court of Appeal upholding it in July.

However, the US Court of Appeals for the Federal Circuit found some patents on the product invalid, potentially paving the way for generic versions of the drug in the US. At the time, Teva said it was considering an appeal to the US Supreme Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

More on this story

Big Pharma
26 November 2013   Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.